REFRESH II AKI

CytoSorb® Reduction of FREee Hemoglobin/Acute Kidney Injury (AKI) During Cardiac Surgery (REFRESH II Trial)

Objective

To study the incidence or severity of acute kidney injury (AKI) in the first 48 hours after cardiopulmonary bypass.

Study Arms

  • Experimental: CytoSorb® Device
  • Placebo Comparator: Control

Eligibility

  • Scheduled for non-emergent cardiac surgery requiring CPB for i) heart valve replacement with any other procedure, without hypothermic circulatory arrest (HCA), or ii) aortic reconstruction with or without another procedure, with HCA

NCT ID

NCT03384875